Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced new orders for the development of two XBAW filters for 5G mobile devices, with deliveries expected in the second half of 2021. This marks the company’s third 5G mobile device customer, highlighting growing interest in its patented XBAW filter technology. The new filters aim to enhance 5G/WiFi coexistence in mid and ultra-high bands. Akoustis is expanding its product catalog, having introduced 15 new filters in 2020, targeting various applications, including WiFi and radar systems.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a new design win for its 5.2/5.6 GHz XBAW RF coexistence filter for a customer’s MU-MIMO Tri-Band WiFi Bridge. Production is anticipated in the second half of 2021. This marks Akoustis's third WiFi 6 design win, following a router launch in November and another customer win earlier in December. The company emphasizes its strategy to become a leading supplier of RF BAW filters for WiFi 6 and 6E applications, driven by a growing interest in its innovative high-frequency XBAW filters.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a design win from a second WiFi 6 customer for its 5.2/5.6 GHz RF coexistence filter solutions. The new tri-band gateway/router leverages multi-user multiple-in-multiple-out (MU-MIMO) technology, requiring multiple filters from Akoustis. Production is expected to start in the first half of 2021. This follows an earlier design win for another customer and reflects a growing sales funnel in the WiFi filter market. CEO Jeff Shealy anticipates additional design wins that could lead to sustainable revenue growth.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the Oppenheimer 5G Summit on December 15, 2020. Senior management will attend virtually due to COVID-19 safety measures. The company is experiencing increased demand for its patented XBAW® RF filters as it progresses into production across various markets, including 5G and high-band WiFi, in 2020. Their product catalog expanded to 15 filters targeting multiple applications. Akoustis is committed to advancing RF filter technology in a growing multi-billion-dollar market.
Akoustis Technologies (NASDAQ: AKTS) announced a redemption notice for its $10 million, 6.5% Convertible Senior Notes, due February 1, 2021. The redemption will cover the principal amount plus accrued interest, amounting to $10.833 per $1,000 of Notes, and a make-whole payment of $184.167. Holders can opt to convert Notes at a rate of 196.08 shares per $1,000 principal amount until January 29, 2021. CEO Jeff Shealy emphasized that eliminating this debt will reduce cash interest expenses by $650,000 annually, enhancing financial flexibility.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the Craig-Hallum Alpha Select Conference on November 17, 2020. The event will take place virtually due to ongoing Covid-19 concerns. Akoustis is witnessing increased interest in its high-frequency, high-performance XBAW filters, which are now in production across various markets, including 5G infrastructure and high-band WiFi. The company has expanded its product catalog by adding 15 filters, showcasing a commitment to innovation in RF filter solutions.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the Roth Technology Virtual Event on November 11, 2020. The company, a leader in bulk acoustic wave (BAW) RF filters, is showcasing its advanced XBAW™ technology that supports high-frequency applications, including 5G infrastructure and high-band WiFi. In 2020, Akoustis added 15 new filters to its catalog to meet growing market demands. Investors interested in connecting with Akoustis management can do so through Roth representatives or by contacting their investor relations.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announces an order for the development of a XBAW™ coexistence filter targeting 5G mobile devices. This project, expected to ramp up in the second half of 2021, comes from a leading RF front-end module maker. The order marks the second engagement from a customer for XBAW™ filters for 5G applications, emphasizing the growing demand for Akoustis' technology. The company is also undergoing a 500% capacity expansion at its Canandaigua, NY facility to meet increasing production needs.
Akoustis Technologies (NASDAQ: AKTS) hosted an investor call on Nov. 2, 2020, to discuss their business update and outlook. The company reported Q1 revenue of $636,000, marking a 74% increase from the previous quarter and 118% from core filter products. However, they incurred a GAAP operating loss of $10.3 million. Key developments include entering production in WiFi 6 and 5G networks, securing several design wins, and expanding their product catalog with 15 new filters. Despite challenges from COVID-19, the company aims for continued growth in top-line revenue.
Akoustis Technologies (AKTS) has received an order for its 3.6 GHz XBAW™ filter solution aimed at enhancing last-mile connectivity for network operators. Following the recent CBRS spectrum auctions, the company is poised for growth as it ramps production in 2021. The XBAW filters are to be used in testing fixed wireless equipment and support the rollout of 5G infrastructure. Akoustis anticipates further customer orders in this burgeoning market, which holds significant potential due to the rising demand among various communication service providers.